Icodextrin: Overview of clinical experience

Peritoneal Dialysis International

Volumn 17, Issue 1, 1997, Pages 22-26

  Peers, Elizabeth ^a   Gokal, Ram ^a  

^a ML Laboratories ^*

Author keywords

Glucose polymer; Icodextrin; Peritoneal dialysis, intraperitoneal vehicle; Ultrafiltration failure

Indexed keywords

DIALYSIS FLUID; ICODEXTRIN; OSMOTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COLLOID; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HUMAN; KIDNEY FAILURE; META ANALYSIS; OSMOSIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; ULTRAFILTRATION;

EID: 0030712252     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089701700108     Document Type: Article

References (28)

1. Gokal R. Osmotic agents in peritoneal dialysis. In: Coles G, Davies M, Williams JD, eds. CAPD: Defence, nutrition and ultrafiltration. Contrib Nephrol 1990; 85:126-33.
2. Kopple J, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47:1148-57.
3. Dobbie J, Lloyd JK, Gall CA. Categorisation of the ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uraemia and CAPD patients. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin 1990; 6:3-12.
4. Mistry CD, Gokal R, Peers EM. A randomized multieentre clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solution in continuous ambulatory peritoneal dialysis: a six month study. Kidney Int 1994; 46:496-503.
5. Posthuma N, ter Wee PM, Donker AJM, et al. Improved ultrafiltration in CCPD using icodextrin instead of glucose during the long daytime dwell. J Amer Soc Nephrol 1995; 6:513.
6. Ota K, Mineshima M, Watanabe N, Naganuma S. Functional deterioration of the peritoneum: does it occur in the absence of peritonitis?Nephrol Dial Transplant 1987; 2:30-3.
7. Mistry CD, Mallick NP, Gokal R. The advantage of glucose polymer as an osmotic agent in continuous peritoneal dialysis. Proc EDTA - ERA 1985; 22:415-20.
8. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; ii:178-82.
9. Mistry CD, Gokal R. Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis? The role for "colloid" osmosis. Clin Sci 1993; 85:495-500.
10. Mistry CD, Gokal R. Icodextrin in peritoneal dialysis: early development and clinical use. Perit Dial Int 1994; 14 (Suppl 2):S13-21.
11. Lundquist A, Ockerman PA, Schersterin B. Fine needle aspiration biopsy of the liver in healthy adults: activity of enzyme of glycogen utilisation and glucose production. Enzymol Bio Clin 1989; 10:8.
12. Hers AG.α-Glucosidase deficiency in generalised glycogen storage disease. Biochem J 1963; 86:11.
13. Mistry CD, Gokal R. Single daily overnight (12-hr dwell) use of 7.5% glucose polymer (Mw 18,700; Mn 7,300) + 0.35% glucose solution: a 3-month study. Nephrol Dial Transplant 1993; 8:443-7.
14. Gokal R, Mistry CD, Peers EM and the MIDAS study group. Peritonitis occurrence in a multicentre study of icodextrin and glucose in CAPD. Perit Dial Int 1995; 15:226-30.
15. Dobbie JW. New concepts in molecular biology and ultrastructural pathology of the peritoneum: their significance for peritoneal dialysis. Am J Kid Dis 1990; 15:97-109.
16. Miller DJ, Dawnay A. Glycation of albumin with icodextrin. J Am Soc Nephrol 1995; 6:551.
17. Mion CM, Slingeneyer A, Canard B. In: Gokal R, ed. Peritonitis in CAPD. Edinburgh: Churchill Livingstone, 1986;163-217.
18. Davies DS. Kinetics of icodextrin. Perit Dial Int 1994; 14 (Suppl 2):S45-50.
19. Stein A, Peers EM, Hattersley J, Harris K, Freehally J, Walls J and the MIDAS study group. Clinical experience with icodextrin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1994; 14 (Suppl 2):S51-4.
20. Peers EM, Scrimgeour AC, Haycox AR. Cost-containment in CAPD patients with ultrafiltration failure. Clin Drug Invest 1995; 10:53-8.
21. Diaz-Buxo JA, Farmer CD, Chandler CT, Walker P, Burgess WP. CCP: Wet is better than dry. Perit Dial Bull 1987; 7 Suppl:S22.
22. Cooper A, Henderson IS, Jones MC. Daytime dwell with 7.5% icodextrin in automated peritoneal dialysis (APD). J EDTNA - ERCA 1995 21 (Suppl 1) 21.
23. Posthuma N, ter Wee PM , Donker AJM, Oe PL, Verbrugh HA. Improved ultrafiltration in CCPD patients using a glucose polymer (GP) instead of glucose (G) as last bag. Kidney Int 1995; 48:1368.
24. Posthuma N, ter Wee PM, Donker AJM, et al. Disaccharide (total maltose) levels in CCPD patients using icodextrin. J Amer Soc Nephrol 1995; 6:513.
25. McArdle CS, Kerr DJ, O'Gorman P, et al. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 1994; 70:762-6.
26. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of the disease. Nature 1993; 362:355-8.
27. Mistry CD, Bhowmick B, Ashman R, Uttley L. Clinical studies of new icodextrin formulations. Perit Dial Int 1994; 14 Suppl 2:S55-7.
28. Ho-dac-Pannekeet MM, Stegeman G, Struijk DG, et al. Peritoneal permeability characteristics using glucose polymer based dialysate.Perit Dial Int 1995; 15 Suppl 36.